Cannabis and schizophrenia;Cannabis und schizophrenie

Sucht

Volumn 48, Issue 5, 2002, Pages 336-345

  Seifert, Jürgen ^a   Schlimme, Jann ^a   Wedegärtner, Felix ^a   Emrich, Hinderk M ^a   Schneider, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cannabis; Endocannabinoids; Psychosis; THC

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; PSYCHOTROPIC AGENT; RESIN;

CULTURAL FACTOR; DETERIORATION; DISEASE COURSE; ECONOMIC ASPECT; HEALTH; HUMAN; MEDICINAL PLANT; POLITICS; PSYCHOSIS; PUBLICATION; RECREATION; REVIEW; SCHIZOPHRENIA;

EID: 0036811870     PISSN: 09395911     EISSN: None     Source Type: Journal    
DOI: 10.1024/suc.2002.48.5.336     Document Type: Review

References (57)

1. Alonso, R., Voutsinos, B., Fournier, M., Labie, C., Steinberg, R., Souilhac, J., Le Fur, G., Soubrie, P. (1999). Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience, 91 (2), 607-620.
2. Andreasson, S., Allebeck, P., Engstrom, A., Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2 (8574), 1483-1486.
3. Axelrod, J., Felder, C. C. (1998). Cannabinoid receptors and their endogenous agonist, anandamide. Neurochemical Research, 23 (5), 575-581.
4. Basu, D., Malhotra, A., Bhagat, A., Varma, V. K. (1999). Cannabis psychosis and acute schizophrenia. A case-control study from India. European Addiction Research, 5 (2), 71-73.
5. Brenneisen, R. (1982). Psychotrope drogen. Pharmaceutical Acta Helvetica, 58, 314-320.
6. Carney, M.W., Bacelle, L., Robinson, B. (1984). Psychosis after cannabis abuse. British Medical Journal of Clinical Research, 288 (6423), 1047.
7. Caspari, D. (1999). Cannabis and schizophrenia: Results of a follow-up study. European Archives of Psychiatry and Clinical Neurosciences, 249 (1), 45-49.
8. Cohen, S.I., Johnson, K. (1988). Psychosis from alcohol or drug abuse. British Medical Journal, 297 (6658), 1270-1271.
9. Davidson, K., Wilson, C. H. (1972). Psychosis associated with cannabis smoking. British Journal of Addiction, 67, 225-228.
10. Dean, B., Sundram, S., Bradbury, R., Scarr, E., Copolov D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103 (1), 9-15.
11. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34, 605-613.
12. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258 (5090), 1946-1949.
13. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372 (6507), 686-691.
14. Di Marzo, V., Melck, D., Bisogno, T., De Petrocellis, L. (1998). Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neurosciences, 21 (12), 521-528.
15. Egan, M. F., Weinberger, D. R. (1997). Neurobiology of schizophrenia. Current Opinion in Neurobiology, 7 (5), 701-707.
16. Eikmeier, G., Lodemann, E. (1991). Cannabiskonsum und verlauf schizophrener psychosen. Sucht, 37 (6), 377-382.
17. Emrich, H. M. (1988). Zur entwicklung einer systemtheorie produktiver psychosen. Nervenarzt, 59, 456-464.
18. Emrich, H. M., Leweke, M., Schneider, U. (1997). Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology, Biochemistry and Behavior, 56 (4), 803-807.
19. Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodriguez de Fonseca, F., Navarro, M., Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosciences, 2 (4), 358-363.
20. Grotenhermen, F. (Hrsg.). (2001). Cannabis und Cannabinoide. Bern: Verlag Hans Huber.
21. Hall, W. & Solowij, N. (1997). Long-term cannabis use and mental health. British Journal of Psychiatry, 171, 107-108.
22. Hambrecht, M., Häfner, H. (2000). Cannabis, vulnerability, and the onset of schizophrenia: An epidemiological perspective. Australian and New Zealand Journal of Psychiatry, 34 (3), 468-475.
23. Harding, T., Knight, F. (1973). Marihuana-modified mania. Archives of General Psychiatry, 29 (5), 635-637.
24. Hüllinghorst, R., (Hrsg.). (1999). Jahrbuch Sucht 2000. Geesthacht: Neuland Verlagsgesellschaft.
25. Imade, A. G., Ebie, J. C. (1991). A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatrica Scandinavica, 83 (2), 134-136.
26. Johns, A. (2001). Psychiatric effects of cannabis. British Journal of Psychiatry, 178, 116-122.
27. Kane, J. M. (1996). Schizophrenia. New England Journal of Medicine, 334 (1), 34-41.
28. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport, 10 (8), 1665-1669.
29. Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., Emrich, H. M. (1999). Effects of synthetic delta-9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology, 142, 230-235.
30. Linszen, D. H., Dingemans, P. M., Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51 (4), 273-279.
31. Mackie, K., Lai, Y., Westenbroek, R., Mitchell, R. (1995). Cannabinoids acivate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabioid receptor. Journal of Neuroscience, 15, 6552-6561.
32. McGuire, P. K., Jones, P., Harvey, I., Bebbington, P., Toone, B., Lewis, S., Murray, R.M. (1994). Cannabis and acute psychosis. Schizophrenia Research, 13 (2), 161-167.
33. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50 (1), 83-90.
34. Navarro, M., Fernandez-Ruiz, J. J., de Miguel, R., Hernandez, M. L., Cebeira, M., Ramos, J. A. (1993). An acute dose of delta-9-tetrahydrocannabinoi affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behavioral Brain Research, 57, 37-47.
35. Negrete, J. C., Knapp, W. P., Douglas, D. E., Smith, W. B. (1986). Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychological Medicine, 16 (3), 515-520.
36. Peralta, V., Cuesta, M.J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scandinavica, 85 (2), 127-130.
37. Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology Therapy, 74 (2), 129-180.
38. Pertwee, R. G. (1999). Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sciences, 65 (6-7), 597-605.
39. Poole, R. & Brabbins, C. (1996). Drug induced psychosis. British Journal of Psychiatry, 168, 135-138.
40. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 22, 350 (2-3), 240-244.
41. Rottanburg, D., Robins, A. H., Ben-Arie, O., Teggin, A., Elk, R. (1982). Cannabis-associated psychosis with hypomanic features. Lancet, 2 (8312), 1364-1366.
42. Sackett D. L., Straus S. E., Richardson W. S., Rosenberg W, Haynes R. B. (2000). Evidence-Based Medicine. London: Churchill Livingstone.
43. Schlimme, J., Rada, D., Schneider, U. (2001). Cannabis consumption and its psychosocial effects in a comparison of different cultures. Fortschritte der Neurologie-Psychiatrie, 69 (8), 367-373.
44. Schneider, U., Borsutzky, M., Seifert, J., Leweke, F. M., Huber, T. J., Rollnik, J. D., Emrich, H. M. (2002). Reduced binocular depth inversion in schizophrenic patients. Schizophrenia Research, 53 (1-2), 101-108.
45. Schneider, U., Leweke, F. M., Mueller-Vahl, K. R., Emrich, H. M. (1998). Cannabinoid/Anandamide-system and schizophrenia: Is there evidence for an association? Pharmacopsychiatry Supplement. 31, 110-113.
46. Schultes, R. E., Hofmann, A. (1987). Pflanzen der Götter: Der Nektar der Verzückung, (S. 92-101). Bern und Stuttgart: Hallwag Verlag.
47. Sedvall, G., Farde, L. (1995) Chemical brain anatomy in schizophrenia. Lancet, 346 (8977), 743-749.
48. Shen, M., Piser, T. M., Seybold, V. S., Thayer, S. A. (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neurosciences, 16 (14), 4322-4334.
49. Stefanis, C., Liakos, A., Boulougouris, J., Fink, M., Freedman, A.M. (1976). Chronic hashish use and mental disorder. American Journal of Psychiatry, 133 (2), 225-227.
50. Stringaris, M.G. (1933). Zur klinik der haschischpsychosen. Archiv für Psychiatrie, 100, 523-532.
51. Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., Waku, K. (1996). N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Journal of Lipid Mediators and Cell Signalling, 14 (1-3), 51-56.
52. Täschner, K. L. (1983). Psychopathology and differential diagnosis of so-called Cannabis psychoses. Fortschritte der Neurologie-Psychiatrie, 51 (7), 235-248.
53. Thacore, V.R., Shukla, S.R. (1976). Cannabis psychosis and paranoid schizophrenia. Archives of General Psychiatry, 33 (3), 383-386.
54. Thomas, H. (1993). Psychiatric symptoms in cannabis users. British Journal of Psychiatry, 163, 141-149.
55. Thornicroft, G. (1990). Cannabis and psychosis. Is there epidemiological evidence for an association? British Journal of Psychiatry, 157, 460.
56. Tsai, S. J., Wang, Y. C., Hong, C. J. (2000). Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatric Genetics, 10 (3), 149-151.
57. Voruganti, L. N., Slomka, P., Zabel, P., Mattar, A., Awad, A. G. (2001). Cannabis induced dopamine release: An invivo SPECT study. Psychiatry Research, 107 (3), 173-177.